[HTML][HTML] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY Seiwert, J Fayette, D Cupissol, JM Del Campo… - Annals of oncology, 2014 - Elsevier
Background Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
[引用][C] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY SEIWERT, J FAYETTE, EEW COHEN… - Annals of …, 2014 - pascal-francis.inist.fr
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent
squamous cell carcinoma of the head and neck CNRS Inist Pascal-Francis CNRS Pascal …
squamous cell carcinoma of the head and neck CNRS Inist Pascal-Francis CNRS Pascal …
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY Seiwert, J Fayette, D Cupissol… - Annals of …, 2014 - annalsofoncology.org
Background Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY Seiwert, J Fayette, D Cupissol… - Annals of …, 2014 - pure.johnshopkins.edu
Background: Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
[HTML][HTML] Editor's choice: A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY Seiwert, J Fayette, D Cupissol… - Annals of …, 2014 - ncbi.nlm.nih.gov
Background Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
TY Seiwert, J Fayette, D Cupissol… - Annals of oncology …, 2014 - escholarship.org
BackgroundAfatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
[引用][C] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY Seiwert, J Fayette, D Cupissol, JM del Campo… - Annals of …, 2014 - cir.nii.ac.jp
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent
squamous cell carcinoma of the head and neck | CiNii Research CiNii 国立情報学研究所 …
squamous cell carcinoma of the head and neck | CiNii Research CiNii 国立情報学研究所 …
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
TY Seiwert, J Fayette, D Cupissol… - Annals of Oncology …, 2014 - europepmc.org
Background Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
[PDF][PDF] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY Seiwert, J Fayette, D Cupissol… - Annals of …, 2014 - pdfs.semanticscholar.org
Background: Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
[PDF][PDF] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY Seiwert, J Fayette, D Cupissol… - Annals of …, 2014 - researchgate.net
Background: Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …